沙特阿拉伯的癌症管理：沙特肿瘤健康经济学专家小组（SHARP）的建议
Cancer Management in Saudi Arabia: Recommendations by the Saudi Oncology HeAlth Economics ExpeRt GrouP (SHARP).
作者信息
Alkhudair Nora, Alshamrani Majed, Samarkandi Hadeel, Almodaheem Hajer, Alabdulkarim Hana, Alsaqaaby Mai, Alnajjar Fouad, Alhashem Hashem, Bakkar Mohammed, Bazarbashi Shouki, Alnahedh Mohammed, Alfraih Feras, Alawagi Mohammad, Al-Jedai Ahmed
机构信息
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Pharmaceutical Care Services, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.
出版信息
Saudi Pharm J. 2021 Feb;29(2):115-120. doi: 10.1016/j.jsps.2020.12.005. Epub 2020 Dec 19.
Abstract
Cancer is widely recognized as a major global health problem and is estimated to rank as one of the leading causes of death worldwide. Saudi Arabia has undergone remarkable socioeconomic development in the past 40 years which has contributed to the increase in cancer incidence. The high costs of new oncology medications in combination with uncertainty of long-term effectiveness and safety outcomes highlight the importance of considering value, in terms of clinical outcomes, relative to cost. We convened a group of experts to discuss key factors impacting the current state of cancer management in Saudi Arabia and to agree on a list of recommendations, with a focus on value-based care, considering evidence, patients, and costs.
摘要
癌症被广泛认为是一个主要的全球健康问题，据估计是全球主要死因之一。沙特阿拉伯在过去40年经历了显著的社会经济发展，这导致了癌症发病率的上升。新的肿瘤药物成本高昂，再加上长期有效性和安全性结果的不确定性，凸显了从临床结果角度考虑相对于成本的价值的重要性。我们召集了一组专家，讨论影响沙特阿拉伯癌症管理现状的关键因素，并就一系列建议达成一致，重点是基于价值的医疗，同时考虑证据、患者和成本。
相似文献
1
Cancer Management in Saudi Arabia: Recommendations by the Saudi Oncology HeAlth Economics ExpeRt GrouP (SHARP).
Saudi Pharm J. 2021 Feb;29(2):115-120. doi: 10.1016/j.jsps.2020.12.005. Epub 2020 Dec 19.
2
Revitalizing oncology medications access in Saudi Arabia: Current challenges and recommendations by the Saudi Oncology Pharmacy Assembly.
J Oncol Pharm Pract. 2025 Mar;31(2):245-250. doi: 10.1177/10781552241232697. Epub 2024 Feb 20.
3
State of health economic evaluation research in Saudi Arabia: a review.
Clinicoecon Outcomes Res. 2012;4:177-84. doi: 10.2147/CEOR.S31087. Epub 2012 Jul 5.
4
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.
5
Reporting Quality of Cost-Effectiveness Analyses Conducted in Saudi Arabia: A Systematic Review.
Value Health Reg Issues. 2021 Sep;25:99-103. doi: 10.1016/j.vhri.2020.12.012. Epub 2021 Apr 10.
6
Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP).
BMC Health Serv Res. 2023 Jan 6;23(1):15. doi: 10.1186/s12913-022-08981-5.
7
Developing pharmacists' competencies in Saudi Arabia: A proposed national competency framework to support initial education and professional development.
Curr Pharm Teach Learn. 2022 Oct;14(10):1256-1268. doi: 10.1016/j.cptl.2022.09.010. Epub 2022 Sep 15.
8
Medication Adherence among Patients with Chronic Diseases in Saudi Arabia.
Int J Environ Res Public Health. 2022 Aug 15;19(16):10053. doi: 10.3390/ijerph191610053.
9
The Saudi Consensus for the Management of Cancer-Associated Thromboembolism: A Modified Delphi-Based Study.
TH Open. 2023 Jan 7;7(1):e14-e29. doi: 10.1055/s-0042-1758856. eCollection 2023 Jan.
10
National Guidelines for Colorectal Cancer Screening in Saudi Arabia with strength of recommendations and quality of evidence.
Ann Saudi Med. 2015 May-Jun;35(3):189-95. doi: 10.5144/0256-4947.2015.189.
引用本文的文献
1
To what extent do cancer centres in Arab countries adhere to ASCO/ONS chemotherapy administration safety standards? A multicentre cross-sectional study.
BMJ Open. 2025 Jul 18;15(7):e095072. doi: 10.1136/bmjopen-2024-095072.
2
Treatment Patterns and Clinical Outcomes in Patients with Hodgkin Lymphoma from Saudi Arabia, Türkiye, and South Africa: Subgroup Analysis from the International Multicenter Retrospective B-HOLISTIC Study.
Turk J Haematol. 2024 Dec 2;41(4):211-224. doi: 10.4274/tjh.galenos.2024.2024.0181. Epub 2024 Oct 28.
3
Synthesis and Evaluation of Thiazolyl-indole-2-carboxamide Derivatives as Potent Multitarget Anticancer Agents.
ACS Omega. 2024 Sep 24;9(40):41944-41967. doi: 10.1021/acsomega.4c06889. eCollection 2024 Oct 8.
4
Conceptualization and establishment of value-based healthcare in Saudi Arabia: A scoping review.
J Taibah Univ Med Sci. 2024 Aug 6;19(4):835-846. doi: 10.1016/j.jtumed.2024.07.008. eCollection 2024 Aug.
5
Revitalizing oncology medications access in Saudi Arabia: Current challenges and recommendations by the Saudi Oncology Pharmacy Assembly.
J Oncol Pharm Pract. 2025 Mar;31(2):245-250. doi: 10.1177/10781552241232697. Epub 2024 Feb 20.
6
Access to Medicines and Pharmaceutical Policy in Saudi Arabia: A Scoping Review.
Integr Pharm Res Pract. 2023 Jul 15;12:137-155. doi: 10.2147/IPRP.S410262. eCollection 2023.
7
Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP).
BMC Health Serv Res. 2023 Jan 6;23(1):15. doi: 10.1186/s12913-022-08981-5.
本文引用的文献
1
Implementing Precision Medicine in Community-Based Oncology Programs: Three Models.
J Oncol Pract. 2019 Jun;15(6):325-329. doi: 10.1200/JOP.18.00661. Epub 2019 Feb 25.
2
Trends in the incidence and mortality of cancer in Saudi Arabia.
Saudi Med J. 2018 Dec;39(12):1259-1262. doi: 10.15537/smj.2018.12.23348.
3
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
4
Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience.
Health Policy. 2018 May;122(5):528-532. doi: 10.1016/j.healthpol.2018.02.008. Epub 2018 Mar 8.
5
International Framework for Cancer Patient Advocacy: Empowering Organizations and Patients to Create a National Call to Action on Cancer.
J Glob Oncol. 2015 Oct 28;1(2):83-91. doi: 10.1200/JGO.2015.000398. eCollection 2015 Dec.
6
Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials.
Clin Oncol (R Coll Radiol). 2016 May;28(5):283-91. doi: 10.1016/j.clon.2015.09.010. Epub 2015 Nov 2.
7
Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure.
Value Health. 2015 Jan;18(1):131-6. doi: 10.1016/j.jval.2014.09.007. Epub 2014 Nov 11.
8
Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).
Ann Oncol. 2014 Sep;25(9):1673-1678. doi: 10.1093/annonc/mdu217. Epub 2014 Jun 20.
9
The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.
Blood. 2013 May 30;121(22):4439-42. doi: 10.1182/blood-2013-03-490003. Epub 2013 Apr 25.
10
Why local guidelines?
Urol Ann. 2011 Mar;3 Suppl(Suppl):S1-2. doi: 10.4103/0974-7796.78547.
Zotero 插件